遗传性出血性毛细血管扩张症患者严重出血对静脉贝伐珠单抗有应答吗?文献综述与病例系列
本文采用PRISMA指南进行文献综述,分析8个病例系列和33篇病例报告共195例遗传性出血性毛细血管扩张症(HHT)患者,其中171例(88%)在贝伐珠单抗治疗后出血减少。作者结论认为全身性贝伐珠单抗对HHT严重鼻出血和/或胃肠道出血很有前景,但需谨慎使用,长期副作用尚未在该人群研究,需随机对照研究支持。
要点
- 195例HHT患者中171例(88%)在贝伐珠单抗治疗后出血减少。
- 全身性贝伐珠单抗对HHT严重鼻出血和/或胃肠道出血很有前景。
- 使用贝伐珠单抗需谨慎,长期副作用尚未在该人群研究。
核心结论
- 基于文献综述和本中心病例系列数据,全身性贝伐珠单抗对HHT严重鼻出血和/或胃肠道出血的治疗很有前景。
- 使用贝伐珠单抗这一强效血管生成抑制剂时应谨慎,该人群的长期副作用尚未研究。
- 需要随机对照研究来支持在HHT患者中的结果。
研究设计与样本
- 文献综述按PRISMA声明进行,并纳入本HHT中心的病例系列。
- 最终分析8个病例系列和33篇病例报告的结果。
主要发现
- 195例患者中171例(88%)在贝伐珠单抗治疗后出血减少。
局限性
- 贝伐珠单抗的长期副作用尚未在该人群研究。
- 需要随机对照研究来支持在HHT患者中的结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant genetic disorder, with a wide variety of clinical manifestations due to the presence of multiple arteriovenous manifestations. Severe bleeding from the gastrointestinal (GI) tract and/or epistaxis presents a significant problem in a subgroup of patients and systemic bevacizumab, an angiogenesis inhibitor, has been suggested to benefit these patients. OBJECTIVE: To perform a review of the literature concerning the efficacy of systemic bevacizumab in treatment of bleeding from the nose or GI tract in patients with HHT, including patients from our own HHT-center. METHODS: A literature review was performed using the guideline "Preferred Reporting Items for systematic Reviews and MetaAnalysis statement" (PRISMA). RESULTS: After careful selection, we finally analysed the results of eight case series and 33 case reports. Among 195 patients 171 (88%) had reduced bleeding after bevacizumab. CONCLUSIONS: Based on the literature review and data from our own case series, systemic bevacizumab is very promising as treatment for HHT patients with severe epistaxis and/or GI-bleeding. However, care should be taken using bevacizumab, a potent angiogenesis inhibitor; long-term side effects have not been studied in this population. A randomized controlled study is warranted to support the results in HHT patients.
引用
- Rosenberg T, Fialla AD, Kjeldsen J, et al. Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series. Rhinology. 2019. PMID: 30907391. doi:10.4193/Rhin18.289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。